Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H18ClFN6O2 |
| Molecular Weight | 440.858 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=CC=C1NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)[C@H](CO)C4=CC(F)=C(Cl)C=C4
InChI
InChIKey=RZUOCXOYPYGSKL-GOSISDBHSA-N
InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1
| Molecular Formula | C21H18ClFN6O2 |
| Molecular Weight | 440.858 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=1eb84585-6831-405d-88b2-cef74aaf004e&cKey=22cc177f-4718-4f12-bdf6-a275db718f29&mKey=6ffe1446-a164-476a-92e7-c26446874d93 | https://www.ncbi.nlm.nih.gov/pubmed/27227380
Curator's Comment: description was created based on several sources, including:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=1eb84585-6831-405d-88b2-cef74aaf004e&cKey=22cc177f-4718-4f12-bdf6-a275db718f29&mKey=6ffe1446-a164-476a-92e7-c26446874d93 | https://www.ncbi.nlm.nih.gov/pubmed/27227380
GDC-0994 (RG7842) is a selective inhibitor of ERK1/2, also known as extracellular-signal-regulated kinases. Daily, oral dosing of GDC-0994 results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. GDC-0994 neither increases nor decreases phospho-ERK, suggesting that different ERK inhibitors have alternative mechanisms of action with respect to feedback signaling. GDC-0994 is currently advancing in a Phase 1 trial in patients with solid tumors.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.57 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.66 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.7 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.68 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.17 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
129 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
27.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
179 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
62 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
88.9 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
32.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
20.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
27.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:07:00 GMT 2025
by
admin
on
Mon Mar 31 22:07:00 GMT 2025
|
| Record UNII |
R6AXV96CRH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1453848-26-4
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
EF-78
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
71727581
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
C170364
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL3544964
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
10386
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
R6AXV96CRH
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
DB15281
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
100000174566
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | |||
|
RAVOXERTINIB
Created by
admin on Mon Mar 31 22:07:00 GMT 2025 , Edited by admin on Mon Mar 31 22:07:00 GMT 2025
|
PRIMARY | MedKoo CAT NO. 206065, CAS N).: 1453848-26-4Description: GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (Last update: 9/14/2015). |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Array BioPharma; Developer: Genentech; Class: Anti-neoplastic, Small molecule; Mechanism of Action: Mitogen activated protein kinase 3 inhibitor, Mitogen-activated protein kinase 1 inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA, 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in France, 18 May 2016 Chemical information added
|
